Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One of Jeff's endless worthless tweets today is to notify that the CEO of Nike resigned today due to sinking sales. What about CEO's of company's with sinking share price??????????
REMEMBER THE WUHN
ASNS news Could have positive implications for the deal
Actelis Networks Files $50 Million Mixed Securities Shelf
ASNS news Could have positive implications for the deal
Actelis Networks Files $50 Million Mixed Securities Shelf
FWIW, if anything A snippet from our fearless leader
I had a very productive day at Google Dubai with my colleague Tiago Henriques. We met some 15 years ago when we lived in Barcelona, and now we are both here in Dubai.
— Jeff Robinson, CEO and Chairman of $MRES and $RLAB (@contrariansmind) September 18, 2024
Tiago heads up AI/ML Cloud for Google, Europe, the Middle East, and Africa.
For the 99%, AI has exploded onto the… pic.twitter.com/dcDX8S6hYR
No clue what you are talking about, and I fear you have no clue either.
I posted a tweet from Nick.
LOL True that.
Don't mean to rain on Nick's parade, but if I remember correctly we got similar tweets towards the end of 2023 and early 2024 ---that time it was about working hard on the QI purchase and re-working terms of the deal and the S-1 as well.
Hope he is on a better track this time.
@NicolasLink
Returning from an intensive trip to New York and San Francisco with
@JpBackwell
and
@james_gibbons_
. Including meetings with bankers, lawyers, funders, and more. Our teams are focused, heads down, getting it done! The goal is in sight! $QIND $DRCR $ILUS $SAML
2:31 PM · Sep 17, 2024
@NicolasLink
Returning from an intensive trip to New York and San Francisco with
@JpBackwell
and
@james_gibbons_
. Including meetings with bankers, lawyers, funders, and more. Our teams are focused, heads down, getting it done! The goal is in sight! $QIND $DRCR $ILUS $SAML
2:31 PM · Sep 17, 2024
A sled ride is usually fun.
Is it Sept 16 in Serbia yet? Or is it Dubai?
$SIRC Update: All round shitty news. First, I was fired last week. The circumstances were such that I will be suing Brad. More once that's filed.
— Law Office of Jason Ostendorf LLC (@LawOfficeJasonO) September 14, 2024
This week the judge dismissed the Massey case. It was WITHOUT prejudice. Meaning the judge knows there's a there there, but seems to…
They seem to be very good at that. So they keep doing it.
But they are working very hard.
Have they re-scheduled the Jan 2024 Annual Meeting yet??? LOL
But in all seriousness, I hope it does happen. They can't afford another embarrassment.
IMO, It is a very easy way out for either party-----either do not agree on the company to perform the Fairness Opinion, or just say we have not finished our review of the Purchase Agreement. Why did they not disclose this in the prior tweet?
From the 10 Q-A filed yesterday: ............. On August 30, 2024, we agreed to further extend the non-solicitation and no-shop periods provided in the Term Sheet until October 1, 2024, unless mutually terminated earlier by the parties. The new extension contains a milestone that both parties have completed their review of the stock purchase agreement and provided their comments before September 15, 2024, and a Fairness Opinion provider has been engaged. Should either of the above milestones not be met by September 15, 2024, then the Non-Solicitation and No-Shop provisions will terminate.
From the QIND 10 Q-A filed yesterday: On May 23, 2024, Quality Industrial Corp. entered into a binding term sheet with Actelis Networks, Inc, a Delaware corporation traded on the NASDAQ under the symbol ASNS, pursuant to which Actelis will acquire between 61% to 75% of the issued and outstanding shares of the Company’s share capital. We originally intended to close the transaction, pending regulatory requirements and due diligence, within 60 days. On August 30, 2024, we agreed to further extend the non-solicitation and no-shop periods provided in the Term Sheet until October 1, 2024, unless mutually terminated earlier by the parties. The new extension contains a milestone that both parties have completed their review of the stock purchase agreement and provided their comments before September 15, 2024, and a Fairness Opinion provider has been engaged. Should either of the above milestones not be met by September 15, 2024, then the Non-Solicitation and No-Shop provisions will terminate.
So that begs the question---Why are you still buying while THEY run the company??????
The saying goes: "Bet on the Jockey, not the horse". You have two inexperienced jockeys here IMO
The damn thing hardly even trades anymore.
How much p/e value do you attribute to a company, whose CEO is fixated on sending tweets
of guys in their underwear LOL
REMEMBER THE WUHN
The dog ate all the execution paperwork
ORCA I appreciate your enthusiasm and your putting your money where your mouth is.
However, please explain something to me. As I am sure you have noted, QIND and SAML stock prices are regressing. The longer this ASNS/QIND merger template is taking, the longer SAML has no money to successfully operate the ERT companies. Are those ERT companies producing any product? Are they selling any product? The lower the stock prices of these companies, the lower the book value of the parent company.
Also, part of ILUS Book Value probably includes the value of AL Shoa---But as far as I can tell ILUS has not paid for it yet. Supposedly to be paid with post merger trading stock. Remember the QI purchase fiasco---where ILUS had to restate downwards all its prior financials when the deal did not consumate.
Hoping for the best here, but management has screwed up time after time.
Eventually?????? Definition--adverb http://1.in the end, especially after a long delay, dispute, or series of problems: Eventually refers to an unspecific time when something will be completed,
BIOTECH MEDICS CEO
@anthony88205118
EVENTUALLY $BMCS WILL RAISE SIGNIFICANT CAPITAL TO EXECUTATE ITS RWA COMMODITY INITIATIVES AND BENEFIT INVESTORS #RWA #STOBOX #BIOTECHMEDICS
#TOKENIZATION $BMCS
BIOTECH MEDICS CEO
@anthony88205118
·
57m
$BMCS SOFT LAUNCH AND AWARENESS HAS PRODUCED SOME OPPORTUNITIES THAT MANAGEMENT IS ENTERTAINING... RWA IS AMAZING #COMMODITYVAULTAPP
#STOBOX #BIOTECHMEDICS
#RWATOKENIZATION
So do we get another deal extension tomorrow????
ILUS currently basically at it's low.
Tokenized RWA Market Hits $10 Billion, Draws Major Institutions https://t.co/Lezc4SfunB
— BIOTECH MEDICS CEO (@anthony88205118) August 27, 2024
They keep changing directions so you have to look both ways
They keep changing directions so you have to look both ways
So what's your point? 😀😀
They are trying to put a nice spin on it, but to me seems to be a big disappointment. Wasn't the whole thrust of their "advantage" because this was CBD infused? Who will buy their product if it is just regular?
CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, August 22, 2024 /EINPresswire.com/ -- The Institute of Biomedical Research Corp. (OTC PINK: MRES), a pioneering nutraceutical biotechnology company that delves into the innovative realm of plant-based medicines, healthy food products, and sustainable packaging solutions, is pleased to announce the following updates with its M2Bio Food and Beverage division:
M2Bio Food and Beverage, known for its premium, healthy, and sustainably sourced products, is taking a significant step forward by announcing a strategic shift in its product lineup. After several successful years of exploring CBD-infused food products, the company has decided to discontinue this line and refocus efforts on expanding its core offerings.
This decision is rooted in the complex scientific and regulatory landscape surrounding CBD. While CBD has shown promise in various health applications, particularly in its anti-inflammatory and neuroprotective effects, the challenges associated with its use in food products have proven to be substantial. Research indicates that the bioavailability of CBD when ingested in food can vary widely, leading to inconsistent dosing and efficacy. Furthermore, the ongoing global debate and regulatory uncertainty over the classification of CBD as a food ingredient have added complexity to its marketability.
“We’ve always been committed to innovation, and our foray into the CBD space was driven by a desire to explore its potential benefits in food products,” says M2Bio Food and Beverage CEO Michael Sachar. “However, it’s just as important to recognize when the scientific, regulatory, and logistical challenges outweigh the benefits. By pivoting away from CBD in our food products, we can streamline our operations and focus on what we do best—delivering high-quality, sustainably sourced foods that our customers trust and love.”
This strategic pivot is a response to the challenges encountered and an opportunity to enhance the company’s offerings further. The Liviana® product line, known for its premium, organic ingredients, is poised to benefit from this refocus. Without the complications associated with CBD, M2Bio Food and Beverage anticipates broader distribution opportunities, particularly in international markets where CBD restrictions have previously posed significant barriers.
While the company is stepping back from CBD in food, its commitment to research and development in the health and wellness sector remains steadfast. M2Bio Food and Beverage will continue to explore the therapeutic potential of CBD in topical applications, particularly for pets suffering from skin conditions. Early studies suggest that CBD’s anti-inflammatory properties could relieve pets with dermatitis, a common and often chronic condition.
Jeff Robinson, CEO of M2Bio Sciences, commented on the scientific considerations driving this decision: “The bioavailability and pharmacokinetics of CBD when incorporated into food products present significant challenges. Our research indicates that achieving consistent therapeutic outcomes through ingestion is complex due to variability in absorption and metabolism. By redirecting our focus away from CBD-infused foods, we are positioning ourselves to advance in areas where we can more reliably control and optimize the health benefits of our products. This shift also opens up the entire global market to us, free from the regulatory constraints and distribution barriers that CBD imposed, allowing us to bring our products to consumers worldwide with greater ease and efficiency.”
As M2Bio Food and Beverage embarks on this new chapter, the company is? very optimistic about the future. This strategic decision will unlock new growth opportunities, allowing the company to deliver greater value to its customers, partners, and shareholders.
Maybe he thinks if he says "It's Mine" enough times it's like mining.
I guess with the change of accountants, all filings will be delayed??????
BIOTECH MEDICS CEO
@anthony88205118
$BMCS tier change corrected back to Current Pink tomorrow morning #RWAs #commodityvault #biotechmedics #stobox
Doubt the filings will be late. They've never been late before on anything LOL
Mauiguy2
They gotta be a tad bit embarrassed by their non-performance.
I don't think so.
But don't worry, they will say they have another plan.